These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Rybak MJ; Lomaestro BM; Rotschafer JC; Moellering RC; Craig WA; Billeter M; Dalovisio JR; Levine DP Pharmacotherapy; 2009 Nov; 29(11):1275-9. PubMed ID: 19873687 [TBL] [Abstract][Full Text] [Related]
3. Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Rybak MJ; Le J; Lodise TP; Levine DP; Bradley JS; Liu C; Mueller BA; Pai MP; Wong-Beringer A; Rotschafer JC; Rodvold KA; Maples HD; Lomaestro BM Pharmacotherapy; 2020 Apr; 40(4):363-367. PubMed ID: 32227354 [TBL] [Abstract][Full Text] [Related]
4. Correlation of a Vancomycin Pharmacokinetic Model and Trough Serum Concentrations in Pediatric Patients. Ploessl C; White C; Manasco K Pediatr Infect Dis J; 2015 Oct; 34(10):e244-7. PubMed ID: 26121203 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Rybak MJ; Le J; Lodise TP; Levine DP; Bradley JS; Liu C; Mueller BA; Pai MP; Wong-Beringer A; Rotschafer JC; Rodvold KA; Maples HD; Lomaestro B Clin Infect Dis; 2020 Sep; 71(6):1361-1364. PubMed ID: 32658968 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections. Adane ED; Herald M; Koura F Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478 [TBL] [Abstract][Full Text] [Related]
8. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia. Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370 [TBL] [Abstract][Full Text] [Related]
9. [Therapeutic monitoring of vancomycin in routine clinical practice]. Kacířová I; Grundmann M Vnitr Lek; 2014 Oct; 60(10):846-51. PubMed ID: 25382007 [TBL] [Abstract][Full Text] [Related]
10. Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC? Patel K; Crumby AS; Maples HD Paediatr Drugs; 2015 Apr; 17(2):97-103. PubMed ID: 25644329 [TBL] [Abstract][Full Text] [Related]
11. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Pai MP; Neely M; Rodvold KA; Lodise TP Adv Drug Deliv Rev; 2014 Nov; 77():50-7. PubMed ID: 24910345 [TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion. Waineo MF; Kuhn TC; Brown DL J Clin Pharm Ther; 2015 Jun; 40(3):259-65. PubMed ID: 25865426 [TBL] [Abstract][Full Text] [Related]
14. Vancomycin Trough Concentration as a Predictor of Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: A Meta-analysis of Observational Studies. Prybylski JP Pharmacotherapy; 2015 Oct; 35(10):889-98. PubMed ID: 26497475 [TBL] [Abstract][Full Text] [Related]
15. Evaluating the Relationship between Vancomycin Trough Concentration and 24-Hour Area under the Concentration-Time Curve in Neonates. Tseng SH; Lim CP; Chen Q; Tang CC; Kong ST; Ho PC Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358290 [TBL] [Abstract][Full Text] [Related]
17. Association of Vancomycin AUC/MIC and Trough Concentration With Early Clinical Response in Enterococcus or Coagulase-Negative Staphylococcus Infection: A Prospective Study. Pitayakittiwong C; Sermsappasuk P; Meesing A; Jaisue S J Clin Pharmacol; 2024 Aug; 64(8):1006-1014. PubMed ID: 38639115 [TBL] [Abstract][Full Text] [Related]
18. The Importance of Individualized Vancomycin Dosing to Ensure Optimal Exposure Early in Therapy. Zasowski EJ; Lodise TP J Clin Pharmacol; 2018 Sep; 58(9):1131-1133. PubMed ID: 30024648 [No Abstract] [Full Text] [Related]
19. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Rybak MJ; Lomaestro BM; Rotschafer JC; Moellering RC; Craig WA; Billeter M; Dalovisio JR; Levine DP Clin Infect Dis; 2009 Aug; 49(3):325-7. PubMed ID: 19569969 [TBL] [Abstract][Full Text] [Related]
20. Vancomycin dosing in children: what is the question? Cole TS; Riordan A Arch Dis Child; 2013 Dec; 98(12):994-7. PubMed ID: 23956256 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]